Form 4: Tevogen Bio Holdings Director Receives Restricted Stock Grant

Tevogen Bio Holdings Inc. reports a restricted stock grant to Director Feike Jeffrey L., with vesting tied to significant revenue milestones.

Summary

• Feike Jeffrey L., a Director at Tevogen Bio Holdings Inc. (TVGN), received a grant of 40,000 shares of common stock on July 10, 2026.
• This grant is part of the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan.
• The restricted stock vests in three equal installments, contingent on the reporting person remaining in service and the company achieving specific aggregate revenue targets: $50 million by the first anniversary, $100 million by the second anniversary, and $150 million by the third anniversary of the grant date.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as it aligns director compensation with company revenue growth, but the actual realization of value is contingent on future performance.

Positives

• Director Feike Jeffrey L. has been granted restricted stock, indicating a commitment to long-term performance and alignment with shareholder interests.
• The vesting conditions are tied to substantial revenue milestones ($50M, $100M, $150M), incentivizing growth and financial success for the company.

Negatives

• The vesting of the restricted stock is contingent on future revenue achievements, which are not guaranteed and depend on the company's operational success.

Risks

• Failure to achieve the specified aggregate revenue targets ($50 million, $100 million, $150 million) by the respective anniversaries of the grant date will result in the forfeiture of unvested shares.
• The reporting person's continued service with the Issuer is a prerequisite for vesting, meaning any departure before vesting would lead to forfeiture.

Future Outlook

The future outlook for the vesting of the restricted stock is directly tied to Tevogen Bio Holdings Inc. achieving significant revenue growth targets of $50 million, $100 million, and $150 million by the first, second, and third anniversaries of the grant date, respectively, while the reporting person remains in service.

Industry Context

StockSavvy.ai notes that equity grants tied to revenue milestones are a common practice in the biotechnology and pharmaceutical sectors, aiming to align executive and director compensation with critical business development and commercialization success.

Stakeholder Impact

• Shareholders: The grant incentivizes a key director to focus on revenue growth, potentially leading to increased shareholder value if milestones are met.
• Employees: Successful achievement of revenue targets could lead to broader company growth and potential benefits for employees.
• Management: Aligns director compensation with company performance, fostering a culture of accountability.

Next Steps

• Monitor Tevogen Bio Holdings Inc.'s revenue generation to assess progress towards vesting milestones.
• Observe the continued service of Director Feike Jeffrey L. with the company.

Key Dates

Keywords

Tevogen Bio Holdings, TVGN, Form 4, Restricted Stock Grant, Omnibus Incentive Plan, Director Compensation, Vesting Schedule, Revenue Milestones, Beneficial Ownership